Fluindione is a vitamin K antagonist.1 It inhibits vitamin K epoxide reductase (VKOR; IC50 = 6.6 nM), including VKOR containing certain substitution mutations. Fluindione inhibits platelet and fibrin deposition, as well as prevents β-thromboglobulin release and thrombin-antithrombin complex formation, in an ex vivo model of tissue factor-induced thrombus formation using isolated human whole blood.2 Fluindione has previously been used in the treatment of emboligenic heart disease, deep vein thrombosis, pulmonary embolism, and in the prevention of thromboembolic complications in patients with heart disease.
1.Chen, X., Jin, D.-Y., Stafford, D.W., et al.Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieuBlood132(18)1974-1984(2018) 2.Bossavy, J.P., Sakariassen, K.S., Thalamas, C., et al.Antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis: Effect of anticoagulation level and combination therapy with aspirinArterioscler. Thromb. Vasc. Biol.19(9)2269-2275(1999)